



## Declaration for Patent Application

Docket Number: 1708.0280002/MAC/MBT

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled: Glucuronyl C5-Epimerase, DNA Encoding the Same and Uses Thereof,

the specification of which is attached hereto unless the following box is checked:

- ☒ was filed on December 7, 2001;  
as United States Application Number or PCT International Application Number 10/005,647; and  
was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information that became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f), or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application, which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or PCT international application having a filing date before that of the application on which priority is claimed.

Prior-Foreign Application(s)

Priority Claimed

\_\_\_\_\_  
(Application No.)

\_\_\_\_\_  
(Country)

\_\_\_\_\_  
(Day/Month/Year Filed)

☐ Yes ☐ No

\_\_\_\_\_  
(Application No.)

\_\_\_\_\_  
(Country)

\_\_\_\_\_  
(Day/Month/Year Filed)

☐ Yes ☐ No

Send Correspondence to:




STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934

Direct Telephone Calls to:


(202) 371-2600

Appl. No. To be assigned  
Docket No. 1708.0280002/MAC/MBT


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	Markku JALKANEN
Signature of sole or first inventor	 March 11, 2002 <sup>Date</sup>
Residence	Piispanristi, Finland
Citizenship	Finnish
Mailing Address	Rauvolantie 79, 20760 Piispanristi, Finland
Full name of second inventor	Kamel El DARWISH
Signature of second inventor	 March 11, 2002 <sup>Date</sup>
Residence	Turku, Finland
Citizenship	USA
Mailing Address	Rysäkatu 21 C 7, 20900 Turku, Finland
Full name of third inventor	Ulf LINDAHL
Signature of third inventor	 March 8, 2002 <sup>Date</sup>
Residence	Uppsala, Sweden
Citizenship	Swedish
Mailing Address	Torgvägen 7, S-756 46 Uppsala, Sweden

Appl. No. *To be assigned*  
Docket No. 1708.0280002/MAC/MBT

Full name of fourth inventor	Jin-ping LI
Signature of fourth inventor	 Li
	Date <i>March 8, 2002</i>
Residence	Uppsala, Sweden
Citizenship	Swedish
Mailing Address	Reykjaviksgatan 51, S-752 63 Uppsala, Sweden

PAUSERSMTUNGA 17080028-2 Declaration

**POWER OF ATTORNEY FROM ASSIGNEE**

Biotie Therapies Corp., a corporation of Finland, having a principal place of business at Turku Technology Center, BioCity, Tykistökatu 6, Turku, Finland 20520, is assignee of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee executed on (1) 11.3.2002, (2) 11.3.2002, (3) 8.3.2002, and (4) 8.3.2002 of an invention known as Glucuronyl C5-Epimerase, DNA Encoding the Same and Uses Thereof (Attorney Docket No. 1708.0280001/MAC/MBT), which is disclosed and claimed in a patent application of the same title by the inventors (1) Markku Jalkanen, (2) Kamel El Darwish, (3) Ilfi Lindahl, and (4) Jin-ping Li (said application filed on December 7, 2001 at the U.S. Patent and Trademark Office, having Application Number 10/005,647).

The Assignee hereby appoint the U.S. attorneys associated with **CUSTOMER NUMBER 28393** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbalà, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; John M. Covert, Esq., Reg. No. 38,759; Linda E. Alcorn, Esq., Reg. No. 39,588; Lawrence B. Bugaisky, Esq., Reg. No. 35,086; Donald J. Featherstone, Esq., Reg. No. 33,876; and Robert C. Millonig, Esq., Reg. No. 34,395. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
U.S.A.

Direct phone calls to 202-371-2600.


FOR: Biotie Therapies Corp.

SIGNATURE: \_\_\_\_\_

BY: Markku Jalkanen

TITLE: CEO

DATE: 12 March 2002



# Certificate Under 37 C.F.R. § 3.73(b)

Applicant: Jalkanen et al.

Application No.: 10/005,647

Filed: December 7, 2001

Entitled: Glucuronyl C5-Epimerase, DNA Encoding the Same and Uses Thereof

Biotie Therapies Corp.

, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest, or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An Assignment from the inventors of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: 12 March 2002

Name: 

Title: Markku Jalkanen, CEO

Signature: \_\_\_\_\_